In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK…
In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survivalCARDIFF, UK…
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s TreatmentHOUSTON, TX, Oct.…
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients…
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ:…
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading…
STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),…
NEW YORK, Oct. 16, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape- The global telerehabilitation systems market size is…
KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global…